NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors

Bibliographic Details
Published in:	JAAD International
Main Authors:	Michael S. Chang, MD, Jordan T. Said, MD, Elliot H. Akama-Garren, PhD, Nicole Trepanowski, MD, Ai-Tram N. Bui, MD, Anita Giobbie-Hurder, MS, Nicole R. LeBoeuf, MD, MPH, Rebecca I. Hartman, MD, MPH
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Subjects:	anti-PD-1 anti-PDL-1 atezolizumab avelumab cemiplimab dAE
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666328724001822

Internet